Abstract:
:Age-structured cell population model was introduced to describe cell survival. The impact of the environment on the cell population is represented by drug plasma concentration. A key model variable is the hazard of cell removal that is a subject to the environment effect. The model is capable of describing cohort and random labeling cell survival data. In addition, it accounts for cell loss due to labeling of cell sample, but it lacks ability to describe the effect of label elution on the survival data. The model was applied to red blood cell (RBC) survival data in two groups of Wistar rats obtained by two techniques: cohort labeling using 14C-glycine (N = 4) and random labeling using biotin (N = 8). The Weibull probability density function was selected for the RBC lifespan distribution. The data were simultaneously fitted by the mixed effects model implemented in Monolix 4.3.3. The estimated typical values of RBC lifespan and age were 53.7 and 27.8 days, respectively. A noticeable effect of biotinylation on RBC survival was observed that resulted in a significant difference between the means of individual RBC lifespan for two groups. The model provides a mechanistic framework flexible enough to account for various experimental designs to generate the cell survival data. Despite model qualification using animal data, the model has the same potential to be applied to cell survival data analysis in humans.
journal_name
J Pharmacokinet Pharmacodynjournal_title
Journal of pharmacokinetics and pharmacodynamicsauthors
Krzyzanski W,Wiczling P,Gebre Adoi
10.1007/s10928-017-9520-6subject
Has Abstractpub_date
2017-08-01 00:00:00pages
305-316issue
4eissn
1567-567Xissn
1573-8744pii
10.1007/s10928-017-9520-6journal_volume
44pub_type
杂志文章abstract::Population pharmacokinetic-pharmacodynamic analysis involves nonlinear hierarchical modelling where the mean response in a population and the variability in response from different sources are studied. It generally consists of two model hierarchies: a model for residual error and a model for heterogeneity termed betwe...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-012-9256-2
更新日期:2012-08-01 00:00:00
abstract::Target-mediated drug disposition (TMDD) is frequently reported for therapeutic monoclonal antibodies and is linked to the high affinity and high specificity of antibody molecules for their target. Understanding TMDD of a monoclonal antibody should go beyond the empirical description of its non-linear PK since valuable...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章,评审
doi:10.1007/s10928-009-9129-5
更新日期:2009-10-01 00:00:00
abstract::Significant arterio-venous differences in nicotine concentrations have been observed during and after cigarette smoking, nicotine nasal spray, and intravenous nicotine administration. In this paper we describe a novel mathematical method for estimating arterial blood levels from venous blood level data. The model allo...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1023/a:1020957208071
更新日期:2002-08-01 00:00:00
abstract::A population pharmacokinetic analysis was conducted to characterize the pharmacokinetics of fexofenadine in Japanese pediatric patients (6 months through 16 years) with perennial allergic rhinitis or atopic dermatitis. The dataset was composed of 515 patients (including 109 adults), for a total of 1,080 concentration-...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 临床试验,杂志文章
doi:10.1007/s10928-014-9356-2
更新日期:2014-04-01 00:00:00
abstract::The pharmacokinetic-pharmacodynamic (PK-PD) relationship of the granulopoietic effects of Filgrastim in healthy volunteers was characterized via a population approach. Healthy male volunteers were enrolled into a four-way crossover clinical trial. Subjects received four single doses of Filgrastim (375 and 750 microgra...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1023/a:1011534529622
更新日期:2001-08-01 00:00:00
abstract::There has been little evaluation of maximum likelihood approximation methods for non-linear mixed effects modelling of count data. The aim of this study was to explore the estimation accuracy of population parameters from six count models, using two different methods and programs. Simulations of 100 data sets were per...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-009-9126-8
更新日期:2009-08-01 00:00:00
abstract::The physiologically based pharmacokinetic (PBPK) models allow for predictive assessment of variability in population of interest. One of the future application of PBPK modeling is in the field of precision dosing and personalized medicine. The aim of the study was to develop PBPK model for amitriptyline given orally, ...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-018-9597-6
更新日期:2018-10-01 00:00:00
abstract::Drugs can affect the cardiovascular (CV) system either as an intended treatment or as an unwanted side effect. In both cases, drug-induced cardiotoxicities such as arrhythmia and unfavourable hemodynamic effects can occur, and be described using mathematical models; such a model informed approach can provide valuable ...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-018-9589-6
更新日期:2018-06-01 00:00:00
abstract::The population approach to estimating mixed effects model parameters of interest in pharmacokinetic (PK) studies has been demonstrated to be an effective method in quantifying relevant population drug properties. The information available for each individual is usually sparse. As such, care should be taken to ensure t...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-005-2102-z
更新日期:2005-02-01 00:00:00
abstract::This study developed an integrated model of severity scores of migraine headache and the incidence of nausea, photophobia, and phonophobia to predict the natural time course of migraine symptoms, which are likely to occur by a common disease progression mechanism. Data were acquired from two phase 3 clinical trials co...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章,随机对照试验
doi:10.1007/s10928-018-9602-0
更新日期:2018-10-01 00:00:00
abstract::A modeling and simulation approach was used for quantitative comparison of a new generation HER2 antibody drug conjugate (ADC, PF-06804103) with trastuzumab-DM1 (T-DM1). To compare preclinical efficacy, the pharmacokinetic (PK)/pharmacodynamic (PD) relationship of PF-06804103 and T-DM1 was determined across a range of...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-020-09702-3
更新日期:2020-10-01 00:00:00
abstract::Regulatory authorities introduced procedures in the last decade for evaluating the bioequivalence (BE) for highly variable drugs. These approaches are similar in principle but differ in details. For example, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) recommend differing regulatory c...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章,评审
doi:10.1007/s10928-019-09623-w
更新日期:2019-04-01 00:00:00
abstract::Pharmacokinetic analysis in humans using compartmental models is restricted with respect to the estimation of parameter values. This is because the experimenter usually is only able to apply inputs and observations in a very small number of compartments in the system. This has implications for the structural identifia...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-012-9291-z
更新日期:2013-02-01 00:00:00
abstract::3-hydroxybenzo(a)pyrene (3-OHBaP) in urine has been proposed as a biomarker of occupational exposure to polycyclic aromatic hydrocarbons. However, to reconstruct exposure doses in workers from biomarker measurements, a thorough knowledge of the kinetics of the benzo(a)pyrene (BaP) and 3-OHBaP given different routes of...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-013-9338-9
更新日期:2013-12-01 00:00:00
abstract::The emerging discipline of mathematical pharmacology occupies the space between advanced pharmacometrics and systems biology. A characteristic feature of the approach is application of advance mathematical methods to study the behavior of biological systems as described by mathematical (most often differential) equati...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-017-9546-9
更新日期:2018-02-01 00:00:00
abstract::Literature data are often reported as multiple (longitudinal) mean outcomes observed in several groups of patients within a study. Observations within a study are correlated because the patients come from a common population, and the mean observations over time within a treatment arm are correlated because they are ba...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-010-9152-6
更新日期:2010-04-01 00:00:00
abstract::We investigated the propagation of population pharmacokinetic information across clinical studies by applying Bayesian techniques. The aim was to summarize the population pharmacokinetic estimates of a study in appropriate statistical distributions in order to use them as Bayesian priors in consequent population pharm...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-005-0048-9
更新日期:2005-08-01 00:00:00
abstract::There are situations in drug development where one may wish to reduce the dimensionality and complexity of whole body physiologically based pharmacokinetic models. A technique for formal reduction of such models, based on global sensitivity analysis, is suggested. Using this approach mean and variance of tissue(s) and...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-005-0004-8
更新日期:2006-02-01 00:00:00
abstract::The volume of distribution at steady state (Vss) of therapeutic proteins is usually assessed by non-compartmental or compartmental pharmacokinetic (PK) analysis wherein errors may arise due to the elimination of therapeutic proteins from peripheral tissues that are not in rapid equilibrium with the sampling compartmen...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-011-9209-1
更新日期:2011-10-01 00:00:00
abstract::The purpose of this study was to develop a whole-body physiologically based pharmacokinetic (WB-PBPK) model for ciprofloxacin for ICU patients, based on only plasma concentration data. In a next step, tissue and organ concentration time profiles in patients were predicted using the developed model. The WB-PBPK model w...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-016-9486-9
更新日期:2017-04-01 00:00:00
abstract::Mathematical modeling of drug effects maximizes the information gained from an experiment, provides further insight into the mechanisms of drug effects, and allows for simulations in order to design studies or even to derive clinical treatment strategies. We reviewed modeling of antimicrobial drug effects and show tha...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章,评审
doi:10.1007/s10928-007-9069-x
更新日期:2007-12-01 00:00:00
abstract::Development of novel therapies for bone diseases can benefit from mathematical models that predict drug effect on bone remodeling biomarkers. Therefore, a bone cycle model (BCM) was developed that takes into consideration the concept of the basic multicellular unit and the dynamic equilibrium of bone remodeling. The m...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-015-9423-3
更新日期:2015-08-01 00:00:00
abstract::Ordinary differential equation models often contain a large number of parameters that must be determined from measurements by estimation procedure. For an estimation to be successful there must be a unique set of parameters that can have produced the measured data. This is not the case if a model is not structurally i...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-019-09624-9
更新日期:2019-04-01 00:00:00
abstract::The distributed delay model has been introduced that replaces the transit compartments in the classic model of chemotherapy-induced myelosuppression with a convolution integral. The maturation of granulocyte precursors in the bone marrow is described by the gamma probability density function with the shape parameter (...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-018-9575-z
更新日期:2018-04-01 00:00:00
abstract::Tocilizumab is a recombinant humanized antihuman interleukin-6 receptor monoclonal antibody, which inhibits binding of IL-6 to its soluble (sIL-6R) and membrane-expressed (mIL-6R) receptors. The work investigated whether the observed decline in peripheral neutrophil and platelet counts after tocilizumab administration...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章,随机对照试验
doi:10.1007/s10928-011-9227-z
更新日期:2012-02-01 00:00:00
abstract::We propose an efficient algorithm for screening covariates in population model building using Wald's approximation to the likelihood ratio test (LRT) statistic in conjunction with Schwarz's Bayesian criterion. The algorithm can be applied to a full model fit of k covariate parameters to calculate the approximate LRT f...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1023/a:1011579109640
更新日期:2001-06-01 00:00:00
abstract::Long term therapy with antiretroviral agents in HIV-infected patients often result in failure to suppress the virus load. Imperfect adherence to prescribed antiviral drugs is an important factor explaining the resurgence of virus. A better understanding of the factors responsible for the virological failure is importa...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-006-9022-4
更新日期:2006-08-01 00:00:00
abstract::In the present pharmacokinetic/pharmacodynamic (PK/PD) evaluation, cortisol, total lymphocytes, and lymphocyte subpopulations were monitored following single oral doses of two oral formulations of 3 mg budesonide (BUD) (Dosage Forms A and B) in order to assess the differential effects that BUD may have on cortisol sup...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-006-9013-5
更新日期:2006-08-01 00:00:00
abstract::Guselkumab, a human IgG1 monoclonal antibody that blocks interleukin-23, has been evaluated in one Phase 2 and two Phase 3 trials in patients with moderate-to-severe psoriasis, in which disease severity was assessed using Psoriasis Area and Severity Index (PASI) and Investigator's Global Assessment (IGA) scores. Throu...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-018-9581-1
更新日期:2018-08-01 00:00:00
abstract::Cancer therapies that harness the actions of the immune response, such as targeted monoclonal antibody treatments and therapeutic vaccines, are relatively new and promising in the landscape of cancer treatment options. Mathematical modeling and simulation of immune-modifying therapies can help to offset the costs of d...
journal_title:Journal of pharmacokinetics and pharmacodynamics
pub_type: 杂志文章
doi:10.1007/s10928-014-9386-9
更新日期:2014-10-01 00:00:00